Double-blind fluoxetine in depressed alcoholic smokers

Jack R. Cornelius, Ihsan M Salloum, Joan G. Ehler, Patricia J. Jarrett, Marie D. Cornelius, Ann Black, James M. Perel, Michael E. Thase

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Treatment trials involving smoking in alcoholics with major depression are scarce, despite the common co-occurrence of these disorders. In this study, 25 smokers with DSM-III-R diagnoses of both major depressive disorder and alcohol dependence were randomized to fluoxetine or placebo in a 12- week, double-blind, parallel group trial. Almost half (48%) of the patients had made a suicide attempt in the week before hospitalization (where recruitment was performed), and 84 percent reported suicidal ideations during that week. Those in the fluoxetine group demonstrated a significant within- group decrease in smoking during the course of the study, whereas those in the placebo group did not. Those in the fluoxetine group smoked 27 percent fewer cigarettes than those in the placebo group, although this difference was not statistically significant. Cumulative alcohol consumption during the 12 weeks of the pharmacotherapy trial was four times as high in the placebo group as in the fluoxetine group, though this difference was not statistically significant in this limited-sized sample. The change in smoking was significantly associated with a change in drinking. These preliminary findings suggest that fluoxetine has the potential for treating the smoking and drinking behaviors of depressed alcoholic smokers.

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalPsychopharmacology Bulletin
Volume33
Issue number1
StatePublished - May 12 1997
Externally publishedYes

Fingerprint

Fluoxetine
Alcoholics
Smoking
Placebos
Drinking Behavior
Suicidal Ideation
Major Depressive Disorder
Tobacco Products
Diagnostic and Statistical Manual of Mental Disorders
Alcohol Drinking
Suicide
Alcoholism
Drinking
Hospitalization
Depression
Drug Therapy

Keywords

  • alcoholism
  • fluoxetine
  • major depression
  • smoking
  • suicidality

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Cornelius, J. R., Salloum, I. M., Ehler, J. G., Jarrett, P. J., Cornelius, M. D., Black, A., ... Thase, M. E. (1997). Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacology Bulletin, 33(1), 165-170.

Double-blind fluoxetine in depressed alcoholic smokers. / Cornelius, Jack R.; Salloum, Ihsan M; Ehler, Joan G.; Jarrett, Patricia J.; Cornelius, Marie D.; Black, Ann; Perel, James M.; Thase, Michael E.

In: Psychopharmacology Bulletin, Vol. 33, No. 1, 12.05.1997, p. 165-170.

Research output: Contribution to journalArticle

Cornelius, JR, Salloum, IM, Ehler, JG, Jarrett, PJ, Cornelius, MD, Black, A, Perel, JM & Thase, ME 1997, 'Double-blind fluoxetine in depressed alcoholic smokers', Psychopharmacology Bulletin, vol. 33, no. 1, pp. 165-170.
Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Black A et al. Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacology Bulletin. 1997 May 12;33(1):165-170.
Cornelius, Jack R. ; Salloum, Ihsan M ; Ehler, Joan G. ; Jarrett, Patricia J. ; Cornelius, Marie D. ; Black, Ann ; Perel, James M. ; Thase, Michael E. / Double-blind fluoxetine in depressed alcoholic smokers. In: Psychopharmacology Bulletin. 1997 ; Vol. 33, No. 1. pp. 165-170.
@article{13e0dbe4b4b74f16a8e33ec56f71d115,
title = "Double-blind fluoxetine in depressed alcoholic smokers",
abstract = "Treatment trials involving smoking in alcoholics with major depression are scarce, despite the common co-occurrence of these disorders. In this study, 25 smokers with DSM-III-R diagnoses of both major depressive disorder and alcohol dependence were randomized to fluoxetine or placebo in a 12- week, double-blind, parallel group trial. Almost half (48{\%}) of the patients had made a suicide attempt in the week before hospitalization (where recruitment was performed), and 84 percent reported suicidal ideations during that week. Those in the fluoxetine group demonstrated a significant within- group decrease in smoking during the course of the study, whereas those in the placebo group did not. Those in the fluoxetine group smoked 27 percent fewer cigarettes than those in the placebo group, although this difference was not statistically significant. Cumulative alcohol consumption during the 12 weeks of the pharmacotherapy trial was four times as high in the placebo group as in the fluoxetine group, though this difference was not statistically significant in this limited-sized sample. The change in smoking was significantly associated with a change in drinking. These preliminary findings suggest that fluoxetine has the potential for treating the smoking and drinking behaviors of depressed alcoholic smokers.",
keywords = "alcoholism, fluoxetine, major depression, smoking, suicidality",
author = "Cornelius, {Jack R.} and Salloum, {Ihsan M} and Ehler, {Joan G.} and Jarrett, {Patricia J.} and Cornelius, {Marie D.} and Ann Black and Perel, {James M.} and Thase, {Michael E.}",
year = "1997",
month = "5",
day = "12",
language = "English",
volume = "33",
pages = "165--170",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "1",

}

TY - JOUR

T1 - Double-blind fluoxetine in depressed alcoholic smokers

AU - Cornelius, Jack R.

AU - Salloum, Ihsan M

AU - Ehler, Joan G.

AU - Jarrett, Patricia J.

AU - Cornelius, Marie D.

AU - Black, Ann

AU - Perel, James M.

AU - Thase, Michael E.

PY - 1997/5/12

Y1 - 1997/5/12

N2 - Treatment trials involving smoking in alcoholics with major depression are scarce, despite the common co-occurrence of these disorders. In this study, 25 smokers with DSM-III-R diagnoses of both major depressive disorder and alcohol dependence were randomized to fluoxetine or placebo in a 12- week, double-blind, parallel group trial. Almost half (48%) of the patients had made a suicide attempt in the week before hospitalization (where recruitment was performed), and 84 percent reported suicidal ideations during that week. Those in the fluoxetine group demonstrated a significant within- group decrease in smoking during the course of the study, whereas those in the placebo group did not. Those in the fluoxetine group smoked 27 percent fewer cigarettes than those in the placebo group, although this difference was not statistically significant. Cumulative alcohol consumption during the 12 weeks of the pharmacotherapy trial was four times as high in the placebo group as in the fluoxetine group, though this difference was not statistically significant in this limited-sized sample. The change in smoking was significantly associated with a change in drinking. These preliminary findings suggest that fluoxetine has the potential for treating the smoking and drinking behaviors of depressed alcoholic smokers.

AB - Treatment trials involving smoking in alcoholics with major depression are scarce, despite the common co-occurrence of these disorders. In this study, 25 smokers with DSM-III-R diagnoses of both major depressive disorder and alcohol dependence were randomized to fluoxetine or placebo in a 12- week, double-blind, parallel group trial. Almost half (48%) of the patients had made a suicide attempt in the week before hospitalization (where recruitment was performed), and 84 percent reported suicidal ideations during that week. Those in the fluoxetine group demonstrated a significant within- group decrease in smoking during the course of the study, whereas those in the placebo group did not. Those in the fluoxetine group smoked 27 percent fewer cigarettes than those in the placebo group, although this difference was not statistically significant. Cumulative alcohol consumption during the 12 weeks of the pharmacotherapy trial was four times as high in the placebo group as in the fluoxetine group, though this difference was not statistically significant in this limited-sized sample. The change in smoking was significantly associated with a change in drinking. These preliminary findings suggest that fluoxetine has the potential for treating the smoking and drinking behaviors of depressed alcoholic smokers.

KW - alcoholism

KW - fluoxetine

KW - major depression

KW - smoking

KW - suicidality

UR - http://www.scopus.com/inward/record.url?scp=0030897098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030897098&partnerID=8YFLogxK

M3 - Article

C2 - 9133770

AN - SCOPUS:0030897098

VL - 33

SP - 165

EP - 170

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 1

ER -